Key result
Dialysis is the definitive treatment for hyperkalemia in end-stage renal disease, while intravenous insulin and nebulized albuterol acutely lower serum potassium.
Why the study?
What are the effective management strategies for hyperkalemia in dialysis patients?
What are the effective management strategies for hyperkalemia in dialysis patients?
This review highlights that while dialysis is the definitive treatment for hyperkalemia in ESRD, IV insulin and albuterol are effective for acute reduction, whereas IV bicarbonate and cation exchange resins are not.
This is the authors' abstract. We don't add key points for this paper.
Hyperkalemia is common in patients with end-stage renal disease, and may result in serious electrocardiographic abnormalities. Dialysis is the definitive treatment of hyperkalemia in these patients. Intravenous calcium is used to stabilize the myocardium. Intravenous insulin and nebulized albuterol lower serum potassium acutely, by shifting it into the cells. Despite their widespread use, neither intravenous bicarbonate nor cation exchange resins are effective in lowering serum potassium acutely. Prevention of hyperkalemia currently rests largely upon dietary compliance and avoidance of medications that may promote hyperkalemia. Prolonged fasting may provoke hyperkalemia, which can be prevented by administration of intravenous dextrose.
Answers are grounded in this paper and cite their sources.
May inform acute hyperkalemia protocols in ESRD; leaves open comparative efficacy of adjuncts for prospective trials.
No takes yet. Share an insight, caveat, or question.
Putcha et al. (2007) conducted a review in Hyperkalemia in end-stage renal disease. Management of hyperkalemia was evaluated. Dialysis is the definitive treatment for hyperkalemia in end-stage renal disease, while intravenous insulin and nebulized albuterol acutely lower serum potassium.
Synapse has enriched 10 related papers. Consider them for comparative context: